跳至主要内容
临床试验/ISRCTN76278694
ISRCTN76278694已完成未知

Investigation of the metabolic effects of duodenal resurfacing on insulin resistant women wIth polycystic ovarian syndrome

Imperial College of Science, Technology and Medicine0 个研究点目标入组 30 人开始时间: 2017年11月10日最近更新:

试验速览

阶段
未知
状态
已完成
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
Female

入选标准

  • 1. Female participants
  • 2. Age 18-45
  • 3. Body mass index (BMI) = 30 kg/m2
  • 4. Diagnosis of PCOS based on the NIH Criteria. Require ALL of the following:
  • 4.1. Menstrual irregularity (anovulation or >35 day cycle)
  • 4.2. Clinical or biochemical hyperandrogenism
  • 4.3. Exclusion of other causes other aetiologies of menstrual dysfunction (e.g. thyroid dysfunction, hyperprolactinaemia)
  • 5. Insulin resistance as defined by a 2-hour oral glucose tolerance test glucose concentration of 7.8 mmol/l and/or HOMA-IR = 3.0.
  • 6. Willing to comply with study requirements and able to give informed consent

排除标准

  • 1. Type 1 or Type 2 diabetes mellitus
  • 2. History of any medical, psychological or other condition, or use of any medications, including over-the-counter products, which, in the opinion of the investigators, would either interfere with the study or potentially cause harm to the volunteer. These includes:
  • 2.1. Active H. pylori infection (Participants with active H. pylori may continue with the screening process if they are treated via medication and re-testing verifies the condition has resolved.)
  • 2.2. Previous gastrointestinal surgery that could affect the ability to treat the duodenum such as subjects who have had a Billroth 2, Roux-en-Y gastric bypass, or other similar procedures or conditions
  • 2.3. History of chronic or acute pancreatitis
  • 2.4. Known active hepatitis or active liver disease
  • 2.5. Symptomatic gallstones or kidney stones, acute cholecystitis or history of duodenal inflammatory diseases including Crohn’s Disease and Celiac Disease
  • 2.6. History of coagulopathy, upper gastro-intestinal bleeding conditions such as ulcers, gastric varices, strictures, congenital or acquired intestinal telangiectasia
  • 2.7. Use of anticoagulation therapy (such as warfarin) which cannot be discontinued for 7 days before and 14 days after the procedure
  • 2.8. Use of P2Y12 inhibitors (clopidogrel, pasugrel, ticagrelor) which cannot be discontinued for 14 days before and 14 days after the procedure. Use of aspirin is allowed.
  • 2.9. Unable to discontinue NSAIDs (non-steroidal anti-inflammatory drugs) during treatment through 4-weeks post procedure phase
  • 2.10. Taking corticosteroids or drugs known to affect GI motility (e.g. Metoclopramide)
  • 2.11. Persistent anaemia, defined as haemoglobin< 10 g/dl
  • 2.12. eGFR < 30 ml/min/1.73m2
  • 2.13. Active systemic infection
  • 2.14. Active malignancy within the last 5 years
  • 2.15. Poor candidates for surgery or general anaesthesia
  • 2.16. Active illicit substance abuse or alcoholism
  • 3. Medications affecting insulin sensitivity (oral steroids, metformin, thiazolidinediones, atypical antipsychotics, hormonal contraceptives, weight loss medication) at screening or 6 months previously.
  • 4. Other causes of anovulation (e.g. hypothyroidism, adrenal or pituitary disorders)
  • 5. More than 6 menstrual bleeds within the previous 12 months
  • 6. Current pregnancy or breastfeeding at screening or 6 months previously
  • 7. Smoking at screening or 6 months previously
  • 8. Without access at home to a telephone or other factor likely to interfere with ability to participate reliably in the study
  • 9. Donated blood during the preceding 3 months or intention to do so before the end of the study
  • 10. Any other mental or physical condition which, in the opinion of the Investigator, makes the subject a poor candidate for clinical trial participation

研究者

相似试验